Adrenocortical Activation by 5-Fluorouracil and its Possible Reversal by Thymidine

  • P. Preziosi
  • M. Vacca
Conference paper
Part of the Archives of Toxicology book series (TOXICOLOGY, volume 6)

Abstract

5-Fluorouracil (FU) provokes a long lasting and dose-related increase of plasma corticosterone in the rat which may be considered a stress reaction involving CRH-ACTH release. Thymidine (TdR) believed to act as a specific and effective antidote against FU toxicity, administered i.m. or i.p. at different times before or after the i.p. or i.v. injection of 100 mg/kg FU on a molar basis 0.1 : 1–10.7 : 1 does not antagonize or, at the highest dosage seem to increase the FU induced adrenocortical activation. Thus, the FU adrenal activation is modulated by a mechanism not involving the block of the de novo thymidilate synthesis.

Key words

5-Fluorouracil Thymidine Adrenocortical activation Thymidilate synthetase Thymine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bourke RS, West CR, Chedha G, Tower DB (1973) Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 33: 1735–1736PubMedGoogle Scholar
  2. Di Renzo GF, Schettini G, Preziosi P (1977) Effect of some antineoplastic agents on plasma level of corticosterone, prolactin and thyroid stimulating hormone. Arch Int Pharmacodyn Ther 230: 324–329PubMedGoogle Scholar
  3. Di Renzo GF, Schettini G, Quattrone A, Preziosi P (1979) Modifiche di secrezioni endocrine da alcuni chemioterapici antineoplastici. G Ital Chemioter 26: 259–261PubMedGoogle Scholar
  4. Givener ML, Rochefort JG (1965) An improved assay of corticosterone in rat serum and adrenal tissue. Steroids 6: 45–52Google Scholar
  5. Goldstein A, Aronow L, Kalman SM (1974) Principles of drug action: the basis of pharmacology. Wiley, New York, p 426Google Scholar
  6. Heidelberg (1974) Fluorinated pyrimidines and their nucleosides, chapt 41. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents, part 2. Springer, Berlin Heidelberg New York ( Handbook of experimental pharmacology, XXXVIII, pp 192–231 )Google Scholar
  7. Santi DV, McHenry CS (1972) 5-fluoro-2′-deoxyuridylate: covalent complex with thymidilate synthetase. Proc Natl Acad Sci USA 69: 1855–1857Google Scholar
  8. Woodcock TM, Martin DS, Damin LAM, Kemeny NE, Young CW (1980) Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacological evaluation. Cancer 45: 1135–1143PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • P. Preziosi
    • 1
  • M. Vacca
    • 1
  1. 1.Department of Pharmacology, School of MedicineCatholic UniversityRomeItaly

Personalised recommendations